All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2004-004594-29 | Phase II Study of VELCADETM in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regimen (X05142) | 2009-10-01 | due-trials |
Listed as ongoing, but also has a completion date | 2004-004596-11 | Phase II Study of VELCADETM in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with more than one prior systemic therapy regimen (X05142) | 2008-02-22 | bad-data |
Reported results | 2005-001055-38 | RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE, ALONE OR ASSOCIATED WITH HIGHDOSE CYTARABINE, FOLLOWED BY RESPONSE- AND AGE-TAILORED RADIOTHERAPY FOR IMMUNOCOMPETENT PAT... | 2011-12-17 | due-trials |
Completed, but no date, and reported results | 2006-005794-22 | A CLINICO-PATHOLOGIC STUDY OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA | bad-data | |
Reported results | 2006-005795-41 | A CLINICO-PATHOLOGICAL PHASE II STUDY WITH TRANSLATIONAL ELEMENTS TO INVESTIGATE THE POSSIBLE INFECTIVE CAUSES OF NON-HODGKIN LYMPHOMA OF THE OCULAR ADNEXAE WITH PARTICULAR REFERENCE TO CHLAMYDIA SPE... | 2012-08-02 | due-trials |
Reported results | 2009-011725-14 | IELSG 34: A Multicenter Phase II study to evaluate the clinical activity and the safety profile of everolimus (RAD001) in marginal zone B-cell lymphomas (MZL) EudraCT Number 2009-011725-14 | 2013-05-01 | due-trials |
Other | 2009-011789-26 | A phase II study of R-CHOP with intensive CNS prophylaxis and scrotal irradiation in patients with primary testicular diffuse large B-cell lymphoma | not-yet-due | |
Ongoing | 2009-012432-32 | RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION vs. HIGH-D... | not-yet-due | |
Reported results | 2011-000880-28 | Bendamustine and Rituximab for the treatment of Splenic Marginal Zone Lymphoma. The IELSG-36 phase II prospective study. Bendamustina e Rituximab per il trattamento del Linfoma zona marginale sple... | 2020-12-30 | due-trials |
Other | 2012-004896-38 | A PHASE II STUDY OF CHLORAMBUCIL IN COMBINATION WITH SUBCUTANEOUS RITUXIMAB FOLLOWED BY MAINTENANCE THERAPY WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUC... | not-yet-due | |
Ongoing | 2012-005702-22 | International prospective Phase 2 trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycycline followed by eradication monitorin... | not-yet-due | |
Completed, report not yet due | 2014-003031-19 | An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by autolog... | 2024-03-22 | not-yet-due |
Ongoing | 2015-003168-35 | A PHASE II TRIAL ADDRESSING FEASIBILITY AND ACTIVITY OF CLARITHROMYCIN + LENALIDOMIDE COMBINATION: A FULL ORAL TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) ... | not-yet-due | |
Ongoing | 2016-003116-12 | RANDOMIZED PHASE II TRIAL ON FITNESS AND COMORBIDITY - TAILORED TREATMENT IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (FIORELLA Trial) | not-yet-due | |
Other | 2018-002364-44 | MALIBU trial - Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas | not-yet-due | |
Other | 2019-004396-38 | Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) | not-yet-due |